A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-Associated pulmonary arterial hypertension

Annals of the Rheumatic Diseases

Volumn 75, Issue 8, 2016, Pages 1457-1465

  Sanges, Sébastien ^a,b,c,d   Launay, David ^a,b,c,d   Rhee, Rennie L ^e   Sitbon, Olivier ^f,g,h   Hachulla, Éric ^a,b,c,d   Mouthon, Luc ⁱ   Guillevin, Loïc ⁱ   Rottat, Laurence ^f,g,h   Montani, David ^f,g,h   De Groote, Pascal ^a,b   Cottin, Vincent ^j   Magro, Pascal ^k   Prévot, Grégoire ^l   Bauer, Fabrice ^m   Bergot, Emmanuel ⁿ   Chabanne, Céline ^o   Reynaud Gaubert, Martine ^p   Leroy, Sylvie ^q   Canuet, Matthieu ^r   Sanchez, Olivier ^s   Gut Gobert, Christophe ^t   Dauphin, Claire ^u   Pison, Christophe ^v,w   Boissin, Clément ^x   Habib, Gilbert ^y   Clerson, Pierre ^z   Conesa, François ^z   Cordier, Jean François ^b   Kawut, Steven M ^e   Simonneau, Gerald ^f,g,h   Humbert, Marc ^f,g,h   more..

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Centre National de Reference Maladies Systemiques et Auto immunes Rares Sclerodermie Systemique   (France)

^d UNIVERSITÉ DE LILLE   (France)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g BICÊTRE HOSPITAL   (France)

^h CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j HOSPICES CIVILS DE LYON   (France)

^k UNIVERSITY HOSPITAL OF TOURS   (France)

^l SERVICE DE PNEUMOLOGIE   (France)

^m HÔPITAL CHARLES NICOLLE   (France)

ⁿ CHU CÔTE DE NACRE   (France)

^o PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^p HÔPITAL NORD   (France)

^q PASTEUR HOSPITAL   (France)

^r HÔPITAL CIVIL   (France)

^s HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^t BREST UNIVERSITY HOSPITAL   (France)

^u SERVICE DE RHUMATOLOGIE   (France)

^v GRENOBLE UNIVERSITY HOSPITAL   (France)

^w UNIV GRENOBLE ALPES   (France)

^x HÔPITAL ARNAUD DE VILLENEUVE   (France)

^y TIMONE HOSPITAL   (France)

^z Soladis clinical studies   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FOLLOW UP; HEART FUNCTION TEST; HEART OUTPUT; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SIX MINUTE WALK DISTANCE TEST; SYSTEMIC SCLEROSIS; AGED; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; FRANCE; HEART CATHETERIZATION; HYPERTENSION, PULMONARY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SCLERODERMA, SYSTEMIC; WALK TEST;

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CARDIAC CATHETERIZATION; CARDIAC OUTPUT; FEMALE; FOLLOW-UP STUDIES; FRANCE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SCLERODERMA, SYSTEMIC; WALK TEST;

EID: 84940831274     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207336     Document Type: Article

References (47)

1. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4.
2. Le Pavec J, Humbert M, Mouthon L, et al. Systemic sclerosis-Associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;181:1285-93.
3. Launay D, Sitbon O, Hachulla E, et al. Survival in systemic sclerosis-Associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis 2013;72:1940-6.
4. Hachulla E, Denton CP. Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: An essential component of disease management. Eur Respir Rev 2010;19:314-20.
5. Butland RJ, Pang J, Gross ER, et al. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J Clin Res Ed 1982;284:1607-8.
6. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: A new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919-23.
7. Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society Technical Standard: field walking tests in chronic respiratory disease. Eur Respir J 2014;44:1428-46.
8. Singh SJ, Puhan MA, Andrianopoulos V, et al. An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J 2014;44:1428-46.
9. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-92.
10. Sitbon O, Humbert M, Nunes H, et al. Long-Term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8.
11. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-Associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-63.
12. Humbert M, Sitbon O, Yaïci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010;36: 549-55.
13. Sweiss NJ, Hushaw L, Thenappan T, et al. Diagnosis and management of pulmonary hypertension in systemic sclerosis. Curr Rheumatol Rep 2010;12:8-18.
14. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trial. Ann Intern Med 2000;132:425-34.
15. Oudiz RJ, Schilz RJ, Barst RJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004;126:420-7.
16. Ahmadi-Simab K, Hellmich B, Gross WL. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease. Eur J Clin Invest 2006;36(Suppl 3):44-8.
17. Ghofrani H-A, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330-40.
18. Lefèvre G, Dauchet L, Hachulla E, et al. Survival and prognostic factors in systemic sclerosis-Associated pulmonary hypertension: A systematic review and meta-Analysis: survival and prognosis in SSc-Associated pulmonary hypertension. Arthritis Rheum 2013;65:2412-23.
19. Chung L, Domsic RT, Lingala B, et al. Survival and predictors of mortality in systemic sclerosis-Associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res 2014;66:489-95.
20. Avouac J, Kowal-Bielecka O, Pittrow D, et al. Validation of the 6 min walk test according to the OMERACT filter: A systematic literature review by the EPOSS-OMERACT group. Ann Rheum Dis 2010;69:1360-3.
21. Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol 2011;40:78-83.
22. Schoindre Y, Meune C, Dinh-Xuan AT, et al. Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis. J Rheumatol 2009;36:1481-5.
23. Deuschle K, Weinert K, Becker MO, et al. Six-minute walk distance as a marker for disability and complaints in patients with systemic sclerosis. Clin Exp Rheumatol 2011;29:S53-9.
24. Garin MC, Highland KB, Silver RM, et al. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol 2009;36:330-6.
25. [No authors listed]. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
26. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
27. Goh NSL, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: A simple staging system. Am J Respir Crit Care Med 2008;177:1248-54.
28. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
29. Olschewski H, Hoeper MM, Behr J, et al. Long-Term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med 2010;104:731-40.
30. Simonneau G, Barst RJ, Galie N, et al. Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2002;165:800-4.
31. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
32. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebocontrolled study. The Lancet 2001;358:1119-23.
33. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation 2008;117:3010-19.
34. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan Therapy for Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2004;169:441-7.
35. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-56.
36. Sandoval J, Torbicki A, Souza R, et al. Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension. Pulm Pharmacol Ther 2012;25:33-9.
37. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. N Engl J Med 2005;353:2148-57.
38. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-17.
39. Enright PL, Sherill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1998;158:1384-7.
40. Campo A, Mathai SC, Le Pavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;182:252-60.
41. Humbert M, Lau EMT, Montani D, et al. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 2014;130:2189-208.
42. Dunkler D, Plischke M, Leffondré K, et al. Augmented backward elimination: A pragmatic and purposeful way to develop statistical models. PLoS ONE 2014;9: e113677.
43. Villalba WO, Sampaio-Barros PD, Pereira MC, et al. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest 2007;131:217-22.
44. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? J Am Coll Cardiol 2012;60:1192-201.
45. Martin EA, Barresi R, Byrne BJ, et al. Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. Sci Transl Med 2012;4:162ra155.
46. Ventetuolo CE, Gabler NB, Fritz JS, et al. Are hemodynamics surrogate end points in pulmonary arterial hypertension? Circulation 2014;130: 768-75.
47. Gabler NB, French B, Strom BL, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012;126:349-56.